登录 | 注册    关注公众号  
微信公众号
搜索
 > 【NKG2A】

NKG2A信息

英文名称:NK cell lectin-like receptor subfamily C member 1
中文名称:自然杀伤细胞凝集素样受体亚家族C成员1
靶点别称:CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
上市药物数量:0
临床药物数量:5
最高研发阶段:临床三期

NKG2A产品列表

ACRO质量管理体系
 
评论(1)
NKA-C5245|Cynomolgus NKG2A / CD159a Protein, His Tag
  1. 156XXXXXXX8
  2. 1人赞
  3. 我们采购这个蛋白进行小鼠免疫,后期筛选能够结合猴源NKG2A蛋白的鼠源抗体分子。蛋白入库后,我们进行了纯度检测,纯度能够满足免疫要求。
  4. 2022-06-29
 

NKG2A 分子别名

NKG2A,CD159a,KLRC1,NK cell receptor A

NKG2A 分子背景

NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.

NKG2A 前沿进展

NKG2A临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
BMS-986315 BMS-986315 临床二期 百时美施贵宝 实体瘤, 非小细胞肺癌 详情
Monalizumab NN-8765; IPH-2201; NNC-0141-0000-0100 临床三期 Innate Pharma, 诺和诺德制药 结直肠癌, 腺癌, 非小细胞肺癌, 慢性淋巴细胞白血病, 食管鳞状细胞癌, 小细胞癌, 口腔癌, 鳞状细胞癌, 食道腺癌, 炎性疾病, 头颈癌, 女性生殖系统癌症, 乳腺癌, 类风湿关节炎, 小细胞肺癌, 食道癌, 胃癌, 头颈部鳞状细胞癌, 实体瘤, 血液肿瘤 详情
HY000102 HY-0102; HY-000102 临床一期 上海怀越生物科技有限公司 实体瘤 详情
BRY-805 BRY805; BRY-805 临床一期 海正生物制药有限公司, 浙江博锐生物制药有限公司 实体瘤 详情
S-095029 S-095029 临床二期 Institut De Recherches Internationales Servier 实体瘤, 食道癌, 胃癌, 错配修复基因缺陷型肿瘤, 高微卫星不稳定性癌症, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定